Chinese Hepatolgy ›› 2025, Vol. 30 ›› Issue (7): 930-933.

• Liver Cancer • Previous Articles     Next Articles

An analysis on the prognosis and recurrence of patients with hepatocellular carcinoma after hepatectomy combined with intraperitoneal hyperthermic chemotherapy

LI Zhuang, LIU Yong, ZHU Feng   

  1. Department of General Surgery, Yifu Hospital Affiliated to Nanjing Medical University, Nanjing 211112, China
  • Received:2025-02-15 Online:2025-07-31 Published:2025-08-11
  • Contact: ZHU Feng,Email:zhufeng@njmu.edu.cn

Abstract: Objective To explore the impact of hepatectomy combined with intraperitoneal hyperthermic chemotherapy (HIPEC) on patients with hepatocellular carcinoma. Methods A total of 106 liver cancer patients who were randomly divided into a control group (53 cases) and an observation group (53 cases), using a random number table. The control group received hepatectomy, while the observation group underwent hepatectomy combined with hyperthermic intraperitoneal chemotherapy. The clinical efficacy, tumor markers [carcinoembryonic antigen (CEA), tumor-specific growth factor (TSGF), immune function (CD3+, CD4+, CD8+), liver function [aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin (TBil), direct bilirubin (DBil)], and postoperative recurrence and metastasis were compared between the two groups. Results The observation group showed a significantly higher total effective rate (90.57%) post-treatment, compared to that of 66.04% in the control group (P<0.05). The levels of CEA and TSGF in the observation group were significantly lower [(4.06±0.92) ng/mL vs. (8.31±1.57) ng/mL, (35.28±5.02) U/mL vs. (52.89±6.17) U/mL, P<0.05]. The immune function markers CD3+ and CD4+ levels were significantly higher in the observation group [(73.94±6.83)% vs. (65.89±6.11)%, (39.25±4.73)% vs. (33.12±4.06)%, P<0.05], while CD8+ levels were lower in the observation group [(25.54±3.15)% vs (29.75±3.68)%, P<0.05]. Liver function parameters (AST, ALT, TBil, DBil) were significantly lower in the observation group [(23.78±2.79) U/L vs. (29.06±3.15) U/L, (34.66±3.29) U/L vs. (43.89±4.08) U/L, (33.58±3.42) μmol/L vs. (55.29±5.37) μmol/L, (16.84±2.12) μmol/L vs. (24.05±2.69) μmol/L, P<0.05]. The recurrence rate in the liver and peritoneal implantation metastasis rate in the observation group were 30.19% and 7.55%, respectively, which were notably lower than those of 69.81% and 47.17% in the control group’s (P<0.05). Conclusion Hepatectomy combined with intraperitoneal hyperthermic chemotherapy shows significant clinical advantages in improving the overall treatment efficacy, enhancing tumor markers and immune function, reducing liver function damage, and decreasing the rates of intrahepatic recurrence and abdominal implantation metastasis in patients with hepatocellular carcinoma.

Key words: Hepatectomy, Intraperitoneal hyperthermic chemotherapy, Hepatocellular carcinoma, Tumor markers, Immune function, Liver function